Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thymosin alpha 1 in EGFR+ NSCLC
NCT02906163Phase 2Unknown
- Sponsor
- SciClone Pharmaceuticals (Holdings) Limited
- Start
- Oct 2016
- Primary completion
- Dec 2019
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of thymosin alpha 1 in non-small cell lung cancer (NSCLC) (3 arms), sponsored by SciClone Pharmaceuticals (Holdings) Limited. Primary endpoints: Number of treatment-related adverse events at 4 months and Progression-Free Survival at 12 months. Status: unknown.
02
Drugs
thymosin alpha 1
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02906163.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02906163.